ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE